EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiac SGLT2 Expression and Cell-Type-Specific Responses to Empagliflozin in iPSC-Derived Models of Diabetic Cardiomyopathy

Nan Su iD, Ren Jie Phang iD, Anne M Kong, Richard J MacIsaac iD, Shiang Y Lim iD, Jarmon G Lees iD

Journal of Cardiovascular Development and Disease · 21.07.2026 · 13 (7) · 341

DOI: 10.3390/jcdd13070341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 21.07.2026. Verfasst von Nan Su und 5 weiteren Autor:innen. Beteiligte Einrichtung: O'Brien Institute Department, St Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart Foundation of Australia, National Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium–glucose co-transporter 2 (SGLT2) inhibitors confer cardioprotection in patients with and without diabetes; however, whether SGLT2 is expressed in cardiac tissue and how these drugs act locally in the heart remains unclear. We investigated SGLT2 expression and the effects of empagliflozin in human iPSC-derived cardiac cells exposed to diabetogenic conditions. SGLT2 expression and the effects of empagliflozin were assessed in iPSC-derived cardiomyocytes, endothelial cells, and cardiac fibroblasts under acute diabetogenic conditions using protein expression and metabolic activity assays, and in a multicellular 3D cardiac microtissue model using metabolic activity and contraction analyses. SGLT2 was detected in all three iPSC-derived cardiac cell types with nuclear and perinuclear localisation; no membrane-bound expression was observed. Endothelial cell SGLT2 expression was elevated under diabetogenic conditions. Diabetogenic stress reduced metabolic activity in both cardiomyocytes and endothelial cells; empagliflozin partially rescued endothelial cell metabolic activity but had no effect in cardiomyocytes. Empagliflozin reversed diabetogenic stress-induced cardiac fibroblast activation. 3D cardiac microtissues under diabetogenic conditions exhibited prolonged relaxation time, reduced beat rate variability, and reduced metabolic activity. Empagliflozin maintained metabolic activity at levels comparable to those of the control but did not rescue relaxation time or beat rate variability. The responsiveness of non-myocytes (endothelial cells and cardiac fibroblasts) to empagliflozin, in the absence of any effect on cardiomyocytes, suggests that non-myocyte-mediated mechanisms may contribute to the clinically observed cardioprotection of SGLT2 inhibitors.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorcardiac microtissuediabetic cardiomyopathyempagliflozintype 2 diabetes

Autor:innen und Institutionen

  • O'Brien Institute Department, St Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
  • Department of Medicine at St Vincent's Hospital, Melbourne Medical School, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia.
  • Australian Centre for Accelerating Diabetes Innovations, School of Medicine, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Department of Surgery, Melbourne Medical School, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC 3010, Australia.

ORCID-Profile: Nan Su, Ren Jie Phang, Richard J MacIsaac, Shiang Y Lim, Jarmon G Lees

Förderung

  • National Heart Foundation of Australia
  • National Heart Foundation

Zitieren

APA

Su, N., Phang, R. J., Kong, A. M., MacIsaac, R. J., Lim, S. Y., & Lees, J. G. (2026). Cardiac SGLT2 Expression and Cell-Type-Specific Responses to Empagliflozin in iPSC-Derived Models of Diabetic Cardiomyopathy. Journal of Cardiovascular Development and Disease, 13(7), 341. https://doi.org/10.3390/jcdd13070341

Vancouver

Su N, Phang RJ, Kong AM, MacIsaac RJ, Lim SY, Lees JG. Cardiac SGLT2 Expression and Cell-Type-Specific Responses to Empagliflozin in iPSC-Derived Models of Diabetic Cardiomyopathy. Journal of Cardiovascular Development and Disease. 2026;13(7):341. doi:10.3390/jcdd13070341

BibTeX
@article{Su2026,
  author = {Su, Nan and Phang, Ren Jie and Kong, Anne M and MacIsaac, Richard J and Lim, Shiang Y and Lees, Jarmon G},
  title = {Cardiac SGLT2 Expression and Cell-Type-Specific Responses to Empagliflozin in iPSC-Derived Models of Diabetic Cardiomyopathy},
  journal = {Journal of Cardiovascular Development and Disease},
  year = {2026},
  volume = {13},
  number = {7},
  pages = {341},
  doi = {10.3390/jcdd13070341}
}
Kostenlos starten →